These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

171 related articles for article (PubMed ID: 35897129)

  • 21. The ERACE-PA Global Surveillance Program: Ceftolozane/tazobactam and Ceftazidime/avibactam in vitro Activity against a Global Collection of Carbapenem-resistant Pseudomonas aeruginosa.
    Gill CM; Aktaþ E; Alfouzan W; Bourassa L; Brink A; Burnham CD; Canton R; Carmeli Y; Falcone M; Kiffer C; Marchese A; Martinez O; Pournaras S; Satlin M; Seifert H; Thabit AK; Thomson KS; Villegas MV; Nicolau DP;
    Eur J Clin Microbiol Infect Dis; 2021 Dec; 40(12):2533-2541. PubMed ID: 34291323
    [TBL] [Abstract][Full Text] [Related]  

  • 22. In vitro activity of imipenem/relebactam, meropenem/vaborbactam, ceftazidime/avibactam, cefepime/zidebactam and other novel antibiotics against imipenem-non-susceptible Gram-negative bacilli from Taiwan.
    Kuo SC; Wang YC; Tan MC; Huang WC; Shiau YR; Wang HY; Lai JF; Huang IW; Lauderdale TL
    J Antimicrob Chemother; 2021 Jul; 76(8):2071-2078. PubMed ID: 33956969
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Ceftolozane/tazobactam activity against drug-resistant Enterobacteriaceae and Pseudomonas aeruginosa causing healthcare-associated infections in the Asia-Pacific region (minus China, Australia and New Zealand): report from an Antimicrobial Surveillance Programme (2013-2015).
    Pfaller MA; Shortridge D; Sader HS; Castanheira M; Flamm RK
    Int J Antimicrob Agents; 2018 Feb; 51(2):181-189. PubMed ID: 28993143
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Activity of cefepime/zidebactam against MDR Escherichia coli isolates harbouring a novel mechanism of resistance based on four-amino-acid inserts in PBP3.
    Bhagwat SS; Hariharan P; Joshi PR; Palwe SR; Shrivastava R; Patel MV; Devanga Ragupathi NK; Bakthavatchalam YD; Ramesh MS; Soman R; Veeraraghavan B
    J Antimicrob Chemother; 2020 Dec; 75(12):3563-3567. PubMed ID: 32772098
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The Novel β-Lactam Enhancer Zidebactam Augments the
    Bhagwat SS; Periasamy H; Takalkar SS; Palwe SR; Khande HN; Patel MV
    Antimicrob Agents Chemother; 2019 Apr; 63(4):. PubMed ID: 30670419
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Ceftolozane/tazobactam activity tested against Gram-negative bacterial isolates from hospitalised patients with pneumonia in US and European medical centres (2012).
    Farrell DJ; Sader HS; Flamm RK; Jones RN
    Int J Antimicrob Agents; 2014 Jun; 43(6):533-9. PubMed ID: 24856078
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Efficacy of human-simulated bronchopulmonary exposures of cefepime, zidebactam and the combination (WCK 5222) against MDR Pseudomonas aeruginosa in a neutropenic murine pneumonia model.
    Kidd JM; Abdelraouf K; Nicolau DP
    J Antimicrob Chemother; 2020 Jan; 75(1):149-155. PubMed ID: 31641765
    [TBL] [Abstract][Full Text] [Related]  

  • 28.
    Moya B; Barcelo IM; Cabot G; Torrens G; Palwe S; Joshi P; Umarkar K; Takalkar S; Periasamy H; Bhagwat S; Patel M; Bou G; Oliver A
    Antimicrob Agents Chemother; 2019 May; 63(5):. PubMed ID: 30782985
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Antimicrobial activities of ceftazidime/avibactam, ceftolozane/tazobactam, imipenem/relebactam, meropenem/vaborbactam, and comparators against Pseudomonas aeruginosa from patients with skin and soft tissue infections.
    Sader HS; Castanheira M; Duncan LR; Mendes RE
    Int J Infect Dis; 2021 Dec; 113():279-281. PubMed ID: 34670144
    [TBL] [Abstract][Full Text] [Related]  

  • 30. In vitro activity of cefiderocol, cefepime/enmetazobactam, cefepime/zidebactam, eravacycline, omadacycline, and other comparative agents against carbapenem-non-susceptible Pseudomonas aeruginosa and Acinetobacter baumannii isolates associated from bloodstream infection in Taiwan between 2018-2020.
    Liu PY; Ko WC; Lee WS; Lu PL; Chen YH; Cheng SH; Lu MC; Lin CY; Wu TS; Yen MY; Wang LS; Liu CP; Shao PL; Lee YL; Shi ZY; Chen YS; Wang FD; Tseng SH; Lin CN; Chen YH; Sheng WH; Lee CM; Tang HJ; Hsueh PR
    J Microbiol Immunol Infect; 2022 Oct; 55(5):888-895. PubMed ID: 34521591
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Inoculum effects of cefepime/zidebactam (WCK 5222) and ertapenem/zidebactam (WCK 6777) for Enterobacterales in relation to β-lactamase type and enhancer effect, as tested by BSAC agar dilution.
    Mushtaq S; Vickers A; Chaudhry A; Woodford N; Livermore DM
    J Antimicrob Chemother; 2022 Jun; 77(7):1916-1922. PubMed ID: 35368056
    [TBL] [Abstract][Full Text] [Related]  

  • 32.
    Karlowsky JA; Hackel MA; Wise MG; Six DA; Uehara T; Daigle DM; Cusick SM; Pevear DC; Moeck G; Sahm DF
    Antimicrob Agents Chemother; 2023 Jan; 67(1):e0128122. PubMed ID: 36541767
    [TBL] [Abstract][Full Text] [Related]  

  • 33. In vitro activity of ceftolozane-tazobactam and ceftazidime-avibactam against clinical isolates of meropenem-non-susceptible Pseudomonas aeruginosa: A two-centre study.
    Mirza HC; Hortaç E; Koçak AA; Demirkaya MH; Yayla B; Güçlü AÜ; Başustaoğlu A
    J Glob Antimicrob Resist; 2020 Mar; 20():334-338. PubMed ID: 31568882
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Comparison of antimicrobial activity between ceftolozane-tazobactam and ceftazidime-avibactam against multidrug-resistant isolates of Escherichia coli, Klebsiella pneumoniae, and Pseudomonas aeruginosa.
    Alatoom A; Elsayed H; Lawlor K; AbdelWareth L; El-Lababidi R; Cardona L; Mooty M; Bonilla MF; Nusair A; Mirza I
    Int J Infect Dis; 2017 Sep; 62():39-43. PubMed ID: 28610832
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Antimicrobial activity of high-dose cefepime-tazobactam (WCK 4282) against a large collection of gram-negative organisms collected worldwide in 2018 and 2019.
    Sader HS; Carvalhaes CG; Mendes RE; Castanheira M
    Int J Infect Dis; 2022 Mar; 116():306-312. PubMed ID: 35066163
    [TBL] [Abstract][Full Text] [Related]  

  • 36. In-vitro activity of cefiderocol, cefepime/zidebactam, cefepime/enmetazobactam, omadacycline, eravacycline and other comparative agents against carbapenem-nonsusceptible Enterobacterales: results from the Surveillance of Multicenter Antimicrobial Resistance in Taiwan (SMART) in 2017-2020.
    Lee YL; Ko WC; Lee WS; Lu PL; Chen YH; Cheng SH; Lu MC; Lin CY; Wu TS; Yen MY; Wang LS; Liu CP; Shao PL; Shi ZY; Chen YS; Wang FD; Tseng SH; Lin CN; Chen YH; Sheng WH; Lee CM; Tang HJ; Hsueh PR
    Int J Antimicrob Agents; 2021 Sep; 58(3):106377. PubMed ID: 34166777
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Compassionate use of a novel β-lactam enhancer-based investigational antibiotic cefepime/zidebactam (WCK 5222) for the treatment of extensively-drug-resistant NDM-expressing Pseudomonas aeruginosa infection in an intra-abdominal infection-induced sepsis patient: a case report.
    Dubey D; Roy M; Shah TH; Bano N; Kulshrestha V; Mitra S; Sangwan P; Dubey M; Imran A; Jain B; Velmurugan A; Bakthavatchalam YD; Veeraraghavan B
    Ann Clin Microbiol Antimicrob; 2023 Jul; 22(1):55. PubMed ID: 37408075
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Evaluation of the in vitro activity of WCK 5222 (cefepime/zidebactam) and currently available combination therapies against single- and double-carbapenemase producing Enterobacteriaceae: Expanding the zone of hope.
    Avery LM; Mullane EM; Nicolau DP
    Int J Antimicrob Agents; 2020 Feb; 55(2):105863. PubMed ID: 31870597
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Phenotypic and genotypic profile of ceftolozane/tazobactam-non-susceptible, carbapenem-resistant Pseudomonas aeruginosa.
    Gill CM; Nicolau DP;
    J Antimicrob Chemother; 2022 Dec; 78(1):252-256. PubMed ID: 36411249
    [TBL] [Abstract][Full Text] [Related]  

  • 40. In vitro activity of ceftazidime-avibactam and comparators against Gram-negative bacterial isolates collected in the Asia-Pacific region as part of the INFORM program (2015-2017).
    Ko WC; Stone GG
    Ann Clin Microbiol Antimicrob; 2020 Apr; 19(1):14. PubMed ID: 32238155
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.